BRAIN Biotech AG Appoints New Executive Vice President to Lead Enzyme Products Business

BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, has appointed Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts' enzyme products business, effective September 1, 2025. Jansen-Storbacka succeeds Rod Sears-Black, who retired on January 1, 2025, with BRAIN Biotech CEO Adriaan Moelker temporarily holding the role during the interim period.

This appointment is significant as Jansen-Storbacka brings more than 20 years of experience in biotechnology with extensive expertise in enzyme applications spanning industrial processes, animal nutrition, and home care. His background includes an M.Sc. in Engineering and Management as well as an MBA, positioning him to lead the company's enzyme and fermentation business strategy. As Executive Vice President, he will oversee approximately 140 employees and manage fermentation facilities in the UK along with production sites in continental Europe and the United States.

The leadership change comes at a critical time for BRAIN Biotech Group as it seeks to strengthen its enzyme business and ensure closer integration of research and production activities across the organization. The company operates through two main business segments: BRAINBiocatalysts, which focuses on development, production, and distribution of specialty enzymes, microorganisms, and ingredients, and BRAINBioIncubator, which handles research-intensive development projects and pharmaceuticals. With revenue of €54.6 million in the 2023/24 fiscal year and approximately 300 employees, the company plays a significant role in the biotechnology sector.

Adriaan Moelker, CEO of BRAIN Biotech, emphasized the importance of this appointment, stating that Jansen-Storbacka's broad industry background will be valuable in serving diverse end markets. His international experience and proven leadership skills make him well-suited to lead the enzyme products business. The company's focus on specialty enzymes for food and life sciences industries, along with developing microbial production strains and scalable bioprocesses, positions it at the forefront of sustainable biological solutions. For more information about the company's operations, visit https://www.brain-biotech-group.com.

The appointment reflects BRAIN Biotech's commitment to maintaining leadership in biotechnology innovation and production capabilities. With fermentation facilities and production sites across multiple regions, the company is well-positioned to expand its market presence and drive growth in enzyme applications across various industrial sectors.